133 related articles for article (PubMed ID: 18830613)
1. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Kim JC; Kim DD; Lee YM; Kim TW; Cho DH; Kim MB; Ro SG; Kim SY; Kim YS; Lee JS
Int J Colorectal Dis; 2009 Feb; 24(2):209-18. PubMed ID: 18830613
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
[TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Yoon SN; Roh SA; Cho DH; Kim MB; Hyun YL; Ro S; Kim BS; Kim SY; Kim YS; Kim JC
Hepatogastroenterology; 2010; 57(99-100):657-62. PubMed ID: 20698245
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
7. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
8. Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?
Lee JH; Um JW; Lee JH; Kim SH; Lee ES; Kim YS
Hepatogastroenterology; 2012 Jun; 59(116):1075-8. PubMed ID: 22580657
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
10. Applicability of histoculture drug response assays in colorectal cancer chemotherapy.
Yoon YS; Kim CW; Roh SA; Cho DH; Kim GP; Hong YS; Kim TW; Kim MB; Kim JC
Anticancer Res; 2012 Aug; 32(8):3581-6. PubMed ID: 22843949
[TBL] [Abstract][Full Text] [Related]
11. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
Ji WB; Um JW; Ryu JS; Hong KD; Kim JS; Min BW; Joung SY; Lee JH; Kim YS
Anticancer Res; 2017 May; 37(5):2679-2682. PubMed ID: 28476844
[TBL] [Abstract][Full Text] [Related]
16. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
19. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
